There are current restrictions regarding the prescribing of long-acting insulin analogues in the Czech Republic, with long-acting insulin analogues only reimbursed if current treatment regimens fail to achieve target HbA1c levels below 60 mmol/mol or if patients prescribed human insulins repeatedly experience severe hypoglycaemia. The gene discussed is INS; the disease is Hypoglycemia.